データ
Panectinによるがん抑制効果
Panectinによるがんの免疫誘導
―特許
出願番号/特許番号：特許第6108425号（日本）
知的財産の名称：がん治療のための組替麻疹ウイルス
発明者：甲斐知恵子、米田美佐子、杉山貴紹
契約年月日；2019年12月24日
出願番号/特許番号：10335481（米国）
知的財産の名称：GENE-MODIFIED MEALS VIRUS FOR TUMER TREATMENT USE
発明者：甲斐知恵子、米田美佐子
契約年月日：2019年12月24日
PCT国際出願番号 ：PCT/JP2023/010385
国際出願日 ：2023年3月16日
発明の名称 ：腫瘍溶解性遺伝子改変麻疹ウイルスの新規用途
―論文
【イヌ肺癌】
Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.
Tamura K, Fujiyuki T, Moritoh K, Akimoto H, Iizuka K, Sato H, Asano K, Yoneda M, Kai C.
Sci Rep. 2023 Oct 24;13(1):18168. doi: 10.1038/s41598-023-42305-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597997/
【免疫保有マウス】
Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.
Moritoh K, Shoji K, Amagai Y, Fujiyuki T, Sato H, Yoneda M, Kai C.
Cancer Sci. 2023 May;114(5):2158-2168. doi: 10.1111/cas.15740.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154881/
【イヌ膀胱癌】
Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K, Shoji K, Fujiyuki T, Moritoh K, Tamura K, Yoshida A, Sato H, Yoneda M, Asano K, Kai C.
Res Vet Sci. 2020 Dec;133:313-317. doi: 10.1016/j.rvsc.2020.10.016.
https://www.sciencedirect.com/science/article/pii/S0034528820310547?via%3Dihub
【トリプルネガティブ乳癌】
Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.
Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M, Sato H, Hattori S, Yoneda M, Kai C.
Mol Ther Oncolytics. 2020 Sep 30;19:127-135. doi: 10.1016/j.omto.2020.09.007.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585052/
【膵臓癌】
Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells.
Awano M, Fujiyuki T, Shoji K, Amagai Y, Murakami Y, Furukawa Y, Sato H, Yoneda M, Kai C.
Cancer Sci. 2016 Nov;107(11):1647-1652. doi: 10.1111/cas.13064.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132336/
【イヌ乳癌】
Development of new therapy for canine mammary cancer with recombinant measles virus.
Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A, Ogihara K, Naya Y, Ikeda F, Matsuda H, Sato H, Kai C.
Mol Ther Oncolytics. 2016 Jan 13;3:15022. doi: 10.1038/mto.2015.22.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782952/
【大腸癌】
Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.
Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C.
Sci Rep. 2016 Apr 19;6:24572. doi: 10.1038/srep24572.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835780/
【肺癌】
A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
Fujiyuki T, Yoneda M, Amagai Y, Obayashi K, Ikeda F, Shoji K, Murakami Y, Sato H, Kai C.
Oncotarget. 2015 Sep 22;6(28):24895-903. doi: 10.18632/oncotarget.4366.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694801/
【乳癌】
Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C.
Gene Ther. 2013 Mar;20(3):338-47. doi: 10.1038/gt.2012.44.
https://www.nature.com/articles/gt201244